Navigation Links
Oncolytics Biotech Inc. Announces Positive Clinical Data from U.S.,Phase I REOLYSIN Trial

(MTD), dose limiting toxicity (DLT), and safety profile of REOLYSIN(R) when administered systemically to patients. A secondary objective is to examine any evidence of anti-tumour activity. Eligible patients included those who had been diagnosed with advanced or metastatic solid tumours that are refractory (have not responded) to standard therapy or for which no curative standard therapy exists.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit www.oncolyticsbiotech.com

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company's expectations related to the results of the Phase I US Systemic Administration clinical trial investigating delivery of REOLYSIN(R) for advanced cancers, and the Company's belief as to the potential of REOLYSIN(R) as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN(R) as a cancer treatment, the success and timely completion of clinical studies and trials, actual patient tolerance, the Company's ability to successfully commercialize REOLYSIN(R), uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory
'"/>




Page: 1 2 3

Related medicine technology :

1. Oncolytics Biotech Inc.s Research Collaborators to Present REOLYSIN Clinical Trial Data at ASCO Conference
2. Oncolytics Biotech Inc. Research Collaborators Demonstrate Reovirus/Gemcitabine Combination Has Synergistic Effect Against Human Colon Cancer Cell Lines
3. Oncolytics Biotech Inc. Collaborators to Present Reovirus/Gemcitabine Combination Research at AACR Annual Meeting
4. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
5. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
6. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
7. Beike Biotechnology Study Suggests Adult Stem Cells Show Promise for Peripheral Vascular Disease
8. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
9. Active Biotech presents new pre-clinical data for the 57-57 project at the 8th World Congress on Inflammation
10. New Positive Pre-clinical Data for Active Biotechs RA Project I-3D
11. Prana Biotechnology Presents New Key Findings on PBT2
Post Your Comments:
(Date:5/21/2013)... ALLENTOWN, Pa. , May 21, 2013  Lehigh ... additional TRU-D SmartUVC TM devices, adding to its ... With seven devices taking up residence within the network, ... in the U.S. to proactively combat superbugs and provide ... Short for Total Room Ultraviolet Disinfector, TRU-D – the ...
(Date:5/21/2013)... , May 21, 2013 Sanofi (EURONEXT: ... REGN) today announced that the New England Journal ... study results of dupilumab (SAR231893/REGN668) in patients with moderate-to-severe ... the alpha subunit of the interleukin 4 receptor (IL-4R ... drivers of Th2 (Type 2 helper T cell) immune ...
(Date:5/21/2013)... 2013 Abaxis, Inc. (NasdaqGS: ABAX), a medical ... that Martin Mulroy , chief commercial ... & Veterinary Conference on Wednesday, May 29, 2013 at ... Le Parker Meridien Hotel in New York ... Abaxis develops, manufactures, markets and sells portable blood analysis ...
Breaking Medicine Technology:Lehigh Valley Expands Fleet of Superbug-Slaying Robots 2Lehigh Valley Expands Fleet of Superbug-Slaying Robots 3Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 2Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 3Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 4Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 5Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 6Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 7Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference 2
... VIEW, Calif., June 23 Alexza,Pharmaceuticals, Inc. (Nasdaq: ... present,results of its Phase 2a clinical trial of ... at the 50th Annual Scientific Meeting of,the American ... Boston,Copley Place in Boston, MA. The oral platform ...
... data from,PAREXEL International Corporation (Nasdaq: PRXL ), ... new,industry-sponsored clinical trial initiations, or starts, surged another ... analysis shows that the,biopharmaceutical industry submitted 662 commercial ... clinical studies for drugs in,2007, up from the ...
Cached Medicine Technology:Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting 2PAREXEL Data Reveal A Record High Number of Clinical Trials Initiated 2PAREXEL Data Reveal A Record High Number of Clinical Trials Initiated 3PAREXEL Data Reveal A Record High Number of Clinical Trials Initiated 4PAREXEL Data Reveal A Record High Number of Clinical Trials Initiated 5
(Date:5/21/2013)... Diversity Focus, a non-profit organization striving to improve the ... Creative Corridor region, is releasing results for its 2013 ... Thursday, May 23rd at 10:30 a.m. The survey ... , The survey is a critical component to the ... nurture and retain people of diverse backgrounds, cultures and ...
(Date:5/21/2013)... AURORA, Colo. (May 21, 2013) A paper recently ... and co-written by physicians and scientists at the ... important genetic risk factor for pulmonary fibrosis can be ... lung disease. , Researchers looked at a fairly common ... is a component of the mucous produced by the ...
(Date:5/21/2013)... and technological research So Paulo Research Foundation, FAPESP, based ... estimated in US$ 680 million to support 17 Research, ... up to eleven years, subject to continuation reviews on ... the 17 RIDCs will come from FAPESP and the ... infrastructure). Host institutions will participate in a portion of ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Today, Zane ... HSA and FSA accounts. Zane Benefits, which provides ... benefits, is the leader in defined contribution ... arrangements . , According to Zane Benefits’ website, the ... was signed into law in 2010 and impacts many ...
(Date:5/21/2013)... 2013 While North Carolina is synonymous ... travel guides. Brunswick Plantation & Golf Resort is synonymous ... access to 27 holes of "Top10" championship golf. ... Carolina, knowing the Top 10 from an ... the overwhelming task of selecting the course to play. ...
Breaking Medicine News(10 mins):Health News:Diversity Focus Announces Results from 2013 Creative Corridor Survey at News Conference on Thursday, May 23rd at 10:30 a.m. 2Health News:Researchers find genetic risk factor for pulmonary fibrosis 2Health News:Research at the cutting edge of knowledge 2Health News:Zane Benefits Publishes New Information on HRA, HSA and FSA Accounts 2Health News:Zane Benefits Publishes New Information on HRA, HSA and FSA Accounts 3Health News:Brunswick Plantation & Golf Resort Named in Top 10 Golf Resorts in North Carolina 2
... for diabetes and heart disease, such as high blood ... risk typical of obesity, but they represent only a ... long-term study. The results will be presented Saturday at ... "Some obese persons have a normal cardiovascular risk ...
... ... product line. , ... Germantown, WI (PRWEB) June 19, 2010 -- Ellsworth Adhesives announced today it ... Rapid Seal® line offers high-performance, flexible, chemical resistant sealants that are designed for a ...
... June 2010: Achieving disease remission in patients with ... of socio-economic importance including work productivity and quality ... EULAR 2010, the Annual Congress of the European ... Austrian findings are reported in addition to improvements ...
... ... dedication among healthcare professionals. This awards program salutes the individual health care ... the patients and family members they serve in every sector of the ... Press Club in Washington, D.C., on October 4, where the award winners ...
... for many with low risk disease, researchers find , ... prostate cancer that has a low risk of progression, ... a suitable treatment option, according to a large-scale study ... to treat localized prostate cancer is controversial because, especially ...
... ... Gynecologic Oncologist Mildred Ridgway, MD is now performing a new procedure at Baptist Medical ... Removing uterine fibroids is referred to as a myomectomy, or fibroidectomy. , ... Jackson, MS (Vocus) June 18, ...
Cached Medicine News:Health News:Certain obese people are not at high risk of heart disease, diabetes 2Health News:Ellsworth Adhesives Is Adding PRC Rapid Seal Product Line Offering 2Health News:Targeting disease remission has socio-economic benefits over low disease activity 2Health News:Targeting disease remission has socio-economic benefits over low disease activity 3Health News:Dorland Health People Awards Accepting Entries through Friday, June 25, 2010 2Health News:'Watchful Waiting' Often Best Strategy for Slow-Moving Prostate Cancer 2Health News:GYN Oncologist Uses da Vinci Surgical Robot to Preserve Fertility 2
... Eyes enzymatic cleaner is a ... removes stubborn deposits in as ... eyes enzymatic cleaner contains an ... irritating film on soft contact ...
... These specialty Eraser instruments have been ... with the right tool for situations ... a series of 25 gauge intraocular, ... discrete treatment of target tissues for ...
Wet-Field Hemostatic Eraser bipolar tip, packsize is 10/box....
Titanium. Straight shafts with curved lower tip. Upper tip fits into positioning hole while lower jaw stabilizes the lens. Flat smooth handle with dull finish. Most popular size or model....
Medicine Products: